Quantitative in vitro to in vivo extrapolation of genotoxicity data provides protective estimates of in vivo dose

  • Publication Date :
  • Publication Type : Journal Article
  • Author(s) : Marc A. Beal, Marc Audebert, Tara Barton-Maclaren, Hannah Battaion, Jeffrey C. Bemis, Xuefei Cao, Connie Chen, Stephen D. Dertinger, Roland Froetschl, Xiaoqing Guo, George Johnson, Giel Hendriks, Laure Khoury, Alexandra S. Long, Stefan Pfuhler, Raja S. Settivari, Shamika Wickramasuriya, Paul White
  • Journal Name : Environmental and Molecular Mutagenesis

Abstract

Genotoxicity assessment is a critical component in the development and evaluation of chemicals. Traditional genotoxicity assays (i.e., mutagenicity, clastogenicity, and aneugenicity) have been limited to dichotomous hazard classification, while other toxicity endpoints are assessed through quantitative determination of points-of-departures (PODs) for setting exposure limits. The more recent higher-throughput in vitro genotoxicity assays, many of which also provide mechanistic information, offer a powerful approach for determining defined PODs for potency ranking and risk assessment. In order to obtain relevant human dose context from the in vitro assays, in vitro to in vivo extrapolation (IVIVE) models are required to determine what dose would elicit a concentration in the body demonstrated to be genotoxic using in vitro assays. Previous work has demonstrated that application of IVIVE models to in vitro bioactivity data can provide PODs that are protective of human health, but there has been no evaluation of how these models perform with in vitro genotoxicity data. Thus, the Genetic Toxicology Technical Committee, under the Health and Environmental Sciences Institute, conducted a case study on 31 reference chemicals to evaluate the performance of IVIVE application to genotoxicity data. The results demonstrate that for most chemicals considered here (20/31), the PODs derived from in vitro data and IVIVE are health protective relative to in vivo PODs from animal studies. PODs were also protective by assay target: mutations (8/13 chemicals), micronuclei (9/12), and aneugenicity markers (4/4). It is envisioned that this novel testing strategy could enhance prioritization, rapid screening, and risk assessment of genotoxic chemicals.

 

Read full article here:
Quantitative in vitro to in vivo extrapolation of genotoxicity data provides protective estimates of in vivo dose.
Beal et al. (2022) Environmental and Molecular Mutagenesis. https://doi.org/10.1002/em.22521

Click to learn more about the HESI Genetic Toxicology Technical Committee

Contact Us

Health and Environmental Sciences Institute (HESI)

hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859

740 15th Street NW, Suite 600
Washington, DC 20005

Stay Informed

Sign up for our monthly e-newsletter.